Generic entry into a regulated pharmaceutical market

Iván Moreno Torres, Jaume Puig () and Joan-Ramon Borrell
Additional contact information
Jaume Puig: https://www.upf.edu/web/econ/faculty/-/asset_publisher/6aWmmXf28uXT/persona/id/3418478

Working Papers, Research Center on Health and Economics from Department of Economics and Business, Universitat Pompeu Fabra

Abstract: The aim of this paper is to analyse empirically entry decisions by generic firms into markets with tough regulation. Generic drugs might be a key driver of competition and cost containment in pharmaceutical markets. The dynamics of reforms of patents and pricing across drug markets in Spain are useful to identify the impact of regulations on generic entry. Estimates from a count data model using a panel of 86 active ingredients during the 1999–2005 period show that the drivers of generic entry in markets with price regulations are similar to less regulated markets: generic firms entries are positively affected by the market size and time trend, and negatively affected by the number of incumbent laboratories and the number of substitutes active ingredients. We also find that contrary to what policy makers expected, the system of reference pricing restrains considerably the generic entry. Short run brand name drug price reductions are obtained by governments at the cost of long run benefits from fostering generic entry and post-patent competition into the markets.

Keywords: Entry; Generic Drugs; Pharmaceutical industry; Reference pricing (search for similar items in EconPapers)
JEL-codes: I11 L11 L65 (search for similar items in EconPapers)
Date: 2007-02
New Economics Papers: this item is included in nep-com, nep-hea, nep-ind, nep-ipr, nep-pr~, nep-mic and nep-reg
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://econ-papers.upf.edu/papers/1014.pdf Whole Paper (application/pdf)

Related works:
Working Paper: Generic entry into a regulated pharmaceutical market (2007)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:upf:upfses:1014

Access Statistics for this paper

More papers in Working Papers, Research Center on Health and Economics from Department of Economics and Business, Universitat Pompeu Fabra
Bibliographic data for series maintained by ( this e-mail address is bad, please contact ).